Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

NCT03310957 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03310957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03310957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 27, 2018
Completion date
September 30, 2024
Enrollment
185 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast neoplasms